PubRank

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Clinical Trial ID NCT01526928

PubWeight™ 36.89‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01526928

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015 6.28
2 Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013 2.93
3 Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013 2.90
4 Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012 2.47
5 Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov 2015 2.07
6 Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015 1.67
7 Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res 2015 1.43
8 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
9 Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 2016 1.13
10 EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 2014 1.08
11 Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med 2014 1.06
12 Novel agents and strategies for overcoming EGFR TKIs resistance. Exp Hematol Oncol 2014 1.01
13 Novel agents in development for advanced non-small cell lung cancer. Ther Adv Med Oncol 2014 0.95
14 Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther 2014 0.91
15 Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Cancer Biol Med 2014 0.88
16 Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Transl Lung Cancer Res 2015 0.87
17 EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Devel Ther 2014 0.86
18 Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Onco Targets Ther 2013 0.85
19 Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw 2013 0.83
20 Recent advances in personalized lung cancer medicine. Per Med 2014 0.82
21 Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. Curr Oncol 2012 0.81
22 Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. Ann Transl Med 2015 0.81
23 Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol 2014 0.81
24 Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res 2014 0.80
25 NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget 2015 0.79
26 EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression. Front Oncol 2014 0.79
27 Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. Onco Targets Ther 2016 0.76
28 New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Onco Targets Ther 2016 0.75
Next 100